The mice model market encompasses the biomedical sector focused on the development, genetic engineering, supply, and utilization of mouse models for drug discovery, translational research, and preclinical therapeutic testing. It serves pharmaceutical companies, biotechnology firms, contract research organizations, and academic institutions studying conditions such as oncology, genetic disorders, and immunology.
The global mice model market was valued at USD 1.53 billion in 2024 and reached USD 1.70 billion in 2025, and it is projected to reach USD 2.74 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
The mice model treatment market is primarily driven by the increasing demand for mouse clinical trials (MCTs), the genetic and physiological versatility of mice in preclinical research, rising biopharmaceutical R&D expenditure, and growing personalized oncology research. However, market growth is heavily restrained by ethical concerns surrounding animal welfare, stringent regulatory oversight, and the substantial costs associated with maintaining specialized vivariums and genetic strains. Lucrative opportunities lie in the expanding demand for disease-specific models, the integration of CRISPR/Cas9 gene-editing technologies to create humanized models at scale, and growing biomedical research investments across emerging Asia-Pacific markets. Despite these prospects, the market faces significant challenges from the rapid development and adoption of non-animal testing alternatives, such as in vitro cell models, microfluidic organ-on-a-chip platforms, and advanced in silico computer simulations aimed at minimizing animal usage.
Target customers for the mice model treatment market primarily include biopharmaceutical companies, contract research organizations (CROs), academic institutions, and government research centers engaged in preclinical drug discovery and translational research. These institutional entities require genetically engineered, disease-specific, and humanized mouse models alongside custom therapeutic intervention studies to evaluate drug efficacy, safety, and pharmacokinetics. Their key preferences center on genetic consistency, standardized health status, high reproducibility of experimental results, strict animal welfare compliance, and seamless integration with complex study protocols. Consequently, purchasing behavior is characterized by high-volume, recurring procurement contracts with specialized model providers, long-term research partnerships, and stringent quality control assessments driven by regulatory requirements for preclinical safety testing.
Market entry, expansion, and profitability in the mice model market are heavily shaped by stringent regulatory frameworks, continuous technological innovations, and prevailing economic conditions. Regulators enforce strict animal welfare standards, such as the UK’s ASPA and US FDA guidelines, while simultaneously promoting the 3Rs (Replacement, Reduction, and Refinement) and increasing the acceptance of New Approach Methodologies (NAMs), which can elevate compliance costs or shift demand toward non-animal testing alternatives. Technologically, the market is being transformed by advanced gene-editing tools like CRISPR-Cas9, humanized mouse models, and the integration of AI and machine learning for predictive modeling, requiring continuous research and development investments to maintain competitive advantages. Economically, while expanding pharmaceutical R&D expenditures and rising chronic disease prevalence drive steady baseline demand, high costs associated with specialized breeding, housing infrastructure, and complex genetic engineering can create entry barriers and constrain profit margins, particularly amidst broader economic fluctuations impacting institutional research budgets.
The mice model market is being rapidly transformed by key trends including the adoption of CRISPR/Cas9 gene-editing tools, the expansion of humanized mice models for immuno-oncology, and the integration of artificial intelligence for predictive disease simulation. Key emerging trends focus on patient-derived xenograft (PDX) models for mouse clinical trials (MCTs), which significantly improve translational success in targeted oncology and personalized medicine. These trends are evolving at an accelerated pace, supported by high double-digit growth in genetically engineered segments, rapid biopharmaceutical R&D investments in the Asia-Pacific region, and an overall market projected to expand at a compound annual growth rate (CAGR) of approximately 10% through the mid-2030s.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308
Technological innovations disrupting the mice model treatment market are centered on high-precision genetic engineering, humanization strategies, and AI-driven translational tools. The industry is seeing rapid adoption of CRISPR-Cas9 and next-generation gene editing platforms like TurboKnockout, which significantly reduce breeding timelines and enable complex, target-specific genomic modifications. Simultaneously, advanced humanized mouse models—engrafted with human immune systems or humanized tissues—and patient-derived xenografts (PDX) are gaining massive traction to better replicate human physiology in oncology, immunology, and rare disease research. Concurrently, the integration of microfluidic platforms, automated high-throughput phenotyping, and AI-powered predictive analytics is transforming early-stage drug screening, optimizing target validation, and streamlining preclinical workflows.
In the mice model treatment market, short-term trends are primarily driven by temporary hype surrounding unvalidated consumer biohacking applications, unapproved research-grade peptide testing, and initial speculative waves around novel standalone preclinical compounds that often face high clinical attrition rates. Conversely, long-term structural shifts are firmly anchored in the deep integration of fully humanized mouse models for immuno-oncology and targeted therapeutics, the expansion of drug repurposing and combination therapy platforms, and the regulatory evolution favoring advanced AI-driven computational tools and micro-physiological systems alongside specialized human-in-the-loop models to streamline drug discovery.
Source:https://www.marketsandmarkets.com/Market-Reports/mice-model-market-1308.html
